Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,519,312.50 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Performance

Shares of INSM stock opened at $81.06 on Friday. The company has a market cap of $14.50 billion, a price-to-earnings ratio of -14.61 and a beta of 1.11. The stock has a 50 day simple moving average of $74.29 and a 200-day simple moving average of $73.59. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, equities analysts forecast that Insmed Incorporated will post -5.42 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Morgan Stanley boosted their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday. Guggenheim boosted their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $91.00.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the company. Elequin Capital LP acquired a new stake in shares of Insmed in the 4th quarter worth approximately $28,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC grew its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management acquired a new stake in shares of Insmed in the 4th quarter worth approximately $47,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.